Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 6/20 | 0.51 |
| ▸ | CNR1 | P21554 | 3/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | DHFR | P00374 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | NEK2 | P51955 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | MGAM | O43451 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6072439 | 0.82 | TRPV1 (0.57) | HTR3AAKR1C3CHRNB2CHRNA4CNR2 | |
| SCHEMBL6505529 | 0.82 | MAPT (0.59) | HTR3AAKR1C3KDM4ENPSR1 | |
| SCHEMBL5317286 | 0.81 | AKR1C3 (0.70) | HTR3AAKR1C3CHRNB2CHRNA4DRD3 | |
| Oxalic Acid SCHEMBL8147179 | 0.81 | CHRNB2 (0.63) | HTR3AAKR1C3CHRNB2CHRNA4CNR2 | |
| SCHEMBL8305711 | 0.80 | HTR3A (0.64) | HTR3AAKR1C3CHRNB2CHRNA4CNR2 | |
| SCHEMBL11978706 | 0.80 | HTR3A (0.68) | HTR3AAKR1C3CHRNB2CHRNA4CNR2 | |
| SCHEMBL6072123 | 0.80 | TRPV1 (0.56) | HTR3AAKR1C3CHRNB2CHRNA4CNR2 | |
| SCHEMBL1729026 | 0.79 | CHRM4 (0.59) | HTR3AAKR1C3CHRNB2CHRNA4CNR2 | |
| SCHEMBL5799831 | 0.79 | NOTUM (0.55) | HTR3AAKR1C3KDM4ENOTUMPDE3B | |
| SCHEMBL6931564 | 0.78 | HCRTR1 (0.62) | HTR3AKDM4ENOTUMCYP2C19NEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | claimed |
| WO-2006058338-A2 | 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | WO | claimed |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
| WO-2006058338-A2 | 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | WO | disclosed |
| WO-2005019200-A2 | ARYL PIPERIDINE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005019200-A2 | ARYL PIPERIDINE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | VDAC1, TRPV1, HVCN1 | HTR3A 415/4885AKR1C3 1494/4885CHRNB2 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.